ArticleFrontiers in nutrition2026
Prevalence and longitudinal development of sarcopenic obesity in an Asian obese population: a large bioelectrical impedance analysis study.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sarcopenic obesity (SO), the coexistence of excess adiposity and reduced relative muscle mass, has metabolic and functional implications. Data in Asian populations remain limited. Objectives: To determine SO prevalence using two diagnostic frameworks, identify predictors of SO while avoiding circular inference, and examine longitudinal reclassification in initially non-sarcopenic obese individuals. Methods: Retrospective cohort study of 2,410 adults with BMI ≥ 25 kg/m Results: SO prevalence was 0.12% (AWGS) and 25.02% (adapted ESPEN/EASO), with equivalent prevalence across sexes (females: 25.02%; males: 25.03%; Conclusion: SO affects approximately one in four obese Malaysian adults under the present body composition-based criteria (sex-specific body fat percentage and population-derived lowest-quartile MFR thresholds); this estimate is contingent on the operational definition and is not an externally validated epidemiological prevalence. MFR and BMI are the most clinically informative metrics, but MFR must not be simultaneously used to define and predict SO. Longitudinal BIA monitoring is warranted in obese populations, as a measurable proportion is reclassified within 12 months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.